Literature DB >> 3923814

Lipoprotein and apolipoprotein levels in angiographically defined coronary atherosclerosis.

S B Schmidt, A G Wasserman, R A Muesing, S E Schlesselman, J C Larosa, A M Ross.   

Abstract

Recent studies suggest that apolipoproteins and subfractions of high-density lipoprotein (HDL) cholesterol may be better predictors of atherosclerotic coronary artery disease (CAD) than are plasma cholesterol and total HDL cholesterol. To examine this hypothesis, plasma cholesterol and triglyceride, cholesterol of low-density lipoprotein, HDL and its subfractions 2 and 3, apolipoprotein A-I, the apolipoprotein B of low-density lipoprotein, the ratio of apolipoprotein EII to EIII, and ratios of several of these variables were measured in a selected series of 126 patients (83 men and 43 women) who underwent coronary angiography for suspected CAD. Mean values of many of these variables differed significantly between the men with CAD and the men without significant CAD, when controlled for age, use of beta blockers and diuretic drugs. Using multivariate logistic regression analysis, the only variable that made a significant independent contribution in predicting CAD in men was the ratio of HDL cholesterol to total plasma cholesterol (p less than 0.0001). The mean of this ratio was 0.17 +/- 0.01 mg/dl in the men with CAD and 0.23 +/- 0.02 mg/dl in the male controls. All men with ratios of less than 0.15 mg/dl had significant CAD, defined as 50% or greater luminal diameter narrowing of 1 or more of the major coronary arteries. No measurement was a significant univariate or multivariate predictor of CAD in the women, but the power to detect such predictors was reduced because of small group sizes. In conclusion, the ratio of HDL cholesterol to plasma cholesterol may be superior to many of the more recently described lipoprotein and apolipoprotein-derived predictors of CAD.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3923814     DOI: 10.1016/0002-9149(85)90953-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Genetic analysis of apolipoprotein A-I in two dietary environments.

Authors:  J Blangero; J W MacCluer; C M Kammerer; G E Mott; T D Dyer; H C McGill
Journal:  Am J Hum Genet       Date:  1990-09       Impact factor: 11.025

2.  Sources of interindividual variation in the quantitative levels of apolipoprotein B in pedigrees ascertained through a lipid clinic.

Authors:  G Pairitz; J Davignon; H Mailloux; C F Sing
Journal:  Am J Hum Genet       Date:  1988-09       Impact factor: 11.025

3.  Apolipoprotein E polymorphism and atherosclerosis: insight from a study in octogenarians.

Authors:  J Davignon; D Bouthillier; A C Nestruck; C F Sing
Journal:  Trans Am Clin Climatol Assoc       Date:  1988

4.  The effect of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects.

Authors:  R I Press; J Geller; G W Evans
Journal:  West J Med       Date:  1990-01

5.  Apolipoprotein A and prognosis after myocardial infarction in non-diabetic men.

Authors:  H Pollak; O Arnoldner; W Enenkel; M Fischer; D Trubert-Exinger
Journal:  Klin Wochenschr       Date:  1991-01-04

6.  Serum lipoproteins and apolipoproteins in young normocholesterolaemic, non-diabetic Indian men with myocardial infarction.

Authors:  M Sewdarsen; R K Desai; S Vythilingum; N Shah; M C Rajput
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

7.  High prevalence of hypertriglyceridaemia and apolipoprotein abnormalities in coronary artery disease.

Authors:  M Barbir; D Wile; I Trayner; V R Aber; G R Thompson
Journal:  Br Heart J       Date:  1988-11

8.  Gene expression patterns in peripheral blood correlate with the extent of coronary artery disease.

Authors:  Peter R Sinnaeve; Mark P Donahue; Peter Grass; David Seo; Jacky Vonderscher; Salah-Dine Chibout; William E Kraus; Michael Sketch; Charlotte Nelson; Geoffrey S Ginsburg; Pascal J Goldschmidt-Clermont; Christopher B Granger
Journal:  PLoS One       Date:  2009-09-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.